Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | PDE4A | P27815 | 2/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865096 | 0.91 | ALDH1A1 (0.52) | ALDH1A1LMNAMAPTGPR119SMN1; SMN2 | |
| SCHEMBL5970555 | 0.89 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPTGPR119SMN1; SMN2 | |
| SCHEMBL5970838 | 0.88 | GPR119 (0.52) | ALDH1A1LMNAMAPTGPR119PDE4B | |
| SCHEMBL5971702 | 0.86 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTGPR119SMN1; SMN2 | |
| SCHEMBL4465377 | 0.86 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTGPR119PDE4B | |
| SCHEMBL5864805 | 0.86 | PDE4D (0.50) | ALDH1A1LMNAMAPTGPR119SMN1; SMN2 | |
| SCHEMBL5970747 | 0.85 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTGPR119PDE4B | |
| SCHEMBL5864756 | 0.85 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTGPR119PDE4B | |
| SCHEMBL31216598 | 0.85 | GPR119 (0.64) | ALDH1A1LMNAMAPTGPR119PDE4B | |
| SCHEMBL31216608 | 0.85 | GPR119 (0.64) | ALDH1A1LMNAMAPTGPR119PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| EP-1245564-B1 | BENZAMIDINE DERIVATIVES | SANKYO CO (JP) | 2006-04-05 | — | — | EP | disclosed |
| US-20040248981-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| US-20040010009-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6555556-B1 | N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors | SANKYO COMPANY, LIMITED (JP) | 2003-04-29 | — | — | US | disclosed |
| EP-1245564-A1 | BENZAMIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | ALDH1A1 1382/4885LMNA 1752/4885MAPT 4885/4885 |
| US-20040010009-A1 | Benzamidine derivatives | HABP2, F7, F2 | ALDH1A1 1918/4885LMNA 1709/4885MAPT 4879/4885 |
| US-20040248981-A1 | Benzamidine derivatives | HABP2, F7, F2 | ALDH1A1 1987/4885LMNA 1715/4885MAPT 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.